Jaguar Health Management

Management criteria checks 3/4

Jaguar Health's CEO is Lisa Conte, appointed in Jun 2013, has a tenure of 11.08 years. total yearly compensation is $815.85K, comprised of 70.6% salary and 29.4% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth €394.62. The average tenure of the management team and the board of directors is 3.6 years and 6.3 years respectively.

Key information

Lisa Conte

Chief executive officer

US$815.9k

Total compensation

CEO salary percentage	70.6%
CEO tenure	11.1yrs
CEO ownership	0.002%
Management average tenure	3.6yrs
Board average tenure	6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Lisa Conte's remuneration changed compared to Jaguar Health's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$816k	US$576k	-US$41m
Sep 30 2023	n/a	n/a	-US$40m
Jun 30 2023	n/a	n/a	-US$44m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$1m	US$603k	-US$47m
Sep 30 2022	n/a	n/a	-US$54m
Jun 30 2022	n/a	n/a	-US$54m
Mar 31 2022	n/a	n/a	-US$59m
Dec 31 2021	US$3m	US$527k	-US$53m
Sep 30 2021	n/a	n/a	-US$50m
Jun 30 2021	n/a	n/a	-US$46m
Mar 31 2021	n/a	n/a	-US$42m
Dec 31 2020	US$1m	US$500k	-US$39m
Sep 30 2020	n/a	n/a	-US$35m
Jun 30 2020	n/a	n/a	-US$39m
Mar 31 2020	n/a	n/a	-US$45m
Dec 31 2019	US$1m	US$500k	-US$45m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$43m
Mar 31 2019	n/a	n/a	-US$34m
Dec 31 2018	US$1m	US$480k	-US$32m
Sep 30 2018	n/a	n/a	-US$41m
Jun 30 2018	n/a	n/a	-US$30m
Mar 31 2018	n/a	n/a	-US$24m
Dec 31 2017	US$643k	US$440k	-US$22m

Compensation vs Market: Lisa's total compensation ($USD815.85K) is above average for companies of similar size in the German market ($USD525.52K).

Compensation vs Earnings: Lisa's compensation has been consistent with company performance over the past year.

CEO

Lisa Conte (65 yo)

11.1yrs

Tenure

US$815,854

Compensation

Ms. Lisa A. Conte serves as a Scientific Advisor at Triton Funds LLC. She is a Former Member of Scientific Advisory Board at Triton Funds LLC. She founded Jaguar Health, Inc. (formerly known as Jaguar Anim...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Lisa Conte	Founder	11.1yrs	US$815.85k	0.0023% $ 394.6
Pravin Chaturvedi	Chief Scientific Officer & Chair of Scientific Advisory Board	2.3yrs	US$627.13k	0.00068% $ 116.2
Jonathan Wolin	Chief of Staff	5.7yrs	US$562.79k	0.00064% $ 109.3
Steven King	Chief of Sustainable Supply	9.8yrs	US$491.54k	0.00055% $ 94.0
Carol Lizak	Chief Financial Officer	4.3yrs	no data	0.00036% $ 61.5
Peter Hodge	Senior Director of Investor Relations	no data	no data	no data
Karen Brunke	Executive VP of Corporate & Business Development	2.8yrs	no data	no data
David Sesin	Chief Manufacturing Officer	no data	no data	no data
Ian Wendt	Chief Commercial Officer	3.6yrs	US$557.90k	0% $ 0
Massimo Radaelli	President of Jaguar International	less than a year	no data	no data
Catherine Collis	Senior Vice President of Growth Strategy	less than a year	no data	no data
Darlene Horton	Chief Medical Officer	no data	no data	no data

3.6yrs

Average Tenure

62yo

Average Age

Experienced Management: 1JA's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lisa Conte	Founder	11.1yrs	US$815.85k	0.0023% $ 394.6
Pravin Chaturvedi	Chief Scientific Officer & Chair of Scientific Advisory Board	7.2yrs	US$627.13k	0.00068% $ 116.2
James Bochnowski	Independent Chairman	10.4yrs	US$140.98k	0.00072% $ 123.0
John Micek	Independent Director	8.3yrs	US$101.68k	0.00042% $ 71.7
Anula Jayasuriya	Independent Director	2yrs	US$77.61k	0.00055% $ 94.0
Jonathan Siegel	Independent Director	6.3yrs	US$104.18k	0.00045% $ 76.9
Sandra Swain	Member of Scientific Advisory Board	1.5yrs	no data	no data
Kelly Shanahan	Scientific Advisory Board	1.3yrs	no data	no data
Stacey Tinianov	Member of Scientific Advisory Board	1.2yrs	no data	no data

6.3yrs

Average Tenure

66yo

Average Age

Experienced Board: 1JA's board of directors are considered experienced (6.3 years average tenure).

Jaguar Health Management

Management criteria checks 3/4

Key information

Recent management updates

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Recent updates

Jaguar Health Announces 1-For-60 Reverse Stock Split in Order to Support Compliance with Nasdaq's Listing Standards

First quarter 2024 earnings released: US$0.058 loss per share (vs US$2.39 loss in 1Q 2023)

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. to Report Q1, 2024 Results on May 14, 2024

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration

Jaguar Health Receives Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Full year 2023 earnings released: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

Jaguar Health, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Jaguar Health Receives Notification Letter from The Nasdaq Stock Market LLC

Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health, Inc. announced that it has received $0.06 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.38 loss per share (vs US$8.83 loss in 3Q 2022)

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New major risk - Financial position

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$8.82 loss in 2Q 2022)

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome

Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease

New major risk - Market cap size

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

First quarter 2023 earnings released: US$2.39 loss per share (vs US$30.17 loss in 1Q 2022)

Jaguar Health Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Jaguar Health, Inc. to Report Q1, 2023 Results on May 15, 2023

Jaguar Health, Inc. announced that it has received $1.86 million in funding

Jaguar Health, Inc. announced that it expects to receive $1.86 million in funding

Full year 2022 earnings released

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Jaguar Health, Inc. Provides Updates Regarding its Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (Cid) in Breast Cancer Patients

European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. announced delayed 10-Q filing

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Jaguar Health, Inc. Announces Appointment of Pravin Chaturvedi as Chief Scientific Officer and Chair of the Scientific Advisory Board

Jaguar Health Regains Compliance with Nasdaq Bid Price Requirement

Jaguar Health Explores Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ Covid-19 Recovery Patients in Europe

Jaguar Health Got Letter from Nasdaq Staying Stipulation for Company to Comply with Minimum Bid Price Requirement by Dec. 23

New 90-day high: €0.40

Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Plan to Study, Develop and Commercialize Crofelemer, the Company’s Novel Proprietary Drug, for an Indication of Inflammatory Diarrhea, Initially in Europe

Revenue misses expectations

Third quarter 2020 earnings released: US$0.20 loss per share

Jaguar Health Receives Positive Nasdaq Listing Determination

New 90-day low: €0.24

Jaguar Health, Inc. Announces Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

New 90-day low: €0.26

New 90-day low - €0.34

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age